Medication history of a series of patients with bullous pemphigoid from northern Greece - observations and discussion.
BACKGROUND
Bullous pemphigoid (BP) is an autoimmune bullous disease that mainly affects elderly patients. In this retrospective study, in a series of patients with BP, data on systemic medications were collected in order to investigate a possible association with active BP.


METHODS
Thirty-four patients with BP were studied in two groups. Group A contained patients who were receiving systemic medications and group B contained patients receiving no medications. All sera were examined by immunoassay for the possible existence of anti-BP180NC16a and anti-BP230, prior to the initiation of steroid treatment.


RESULTS
Patients were of a similar age in both groups (P = 0.07). Anti-BP180NC16a autoantibodies were detected in 80% of patients in group A and in 14% of patients in group B. Anti-BP230 autoantibodies were detected in 25% of patients in group A and in 50% of patients in group B. Levels of circulating anti-BP180NC16a autoantibodies were statistically significantly higher in group A than in group B (P = 0.04).


CONCLUSIONS
Patients who were receiving systemic medications seemed to be more susceptible to the development of BP. Should we consider drug exposure as one of the reasons for the increased prevalence of BP in the elderly? It is important to be more vigilant with this category of patients in order to provide an early diagnosis of the disease.
Patsatsi
Aikaterini
A
First Dermatologic Clinic and First Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Greece. kaptz@med.auth.gr, iros@med.auth.gr
Vyzantiadis
Timoleon-Achilleas
TA
Chrysomallis
Fotis
F
Devliotou-Panagiotidou
Despina
D
Sotiriadis
Dimitrios
D
D018674:Adrenergic Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D005260:Female; D006115:Greece / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D024041:Non-Fibrillar Collagens / Q000276:immunology; D010391:Pemphigoid, Bullous / Q000453:epidemiology* / Q000276:immunology*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D000097805:Collagen Type XVII
D018674:Adrenergic Antagonists; D000925:Anticoagulants; D000959:Antihypertensive Agents; D001323:Autoantibodies; D001324:Autoantigens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D024041:Non-Fibrillar Collagens; D000097805:Collagen Type XVII